A Research Study for Patients With Overactive Bladder | NCT00168454 | Trialant
CompletedInterventionalPhase 2Updated Nov 6, 2013
A Research Study for Patients With Overactive Bladder
ClinicalTrials.gov ID
NCT00168454
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
313Actual
Last Update Posted
Nov 6, 2013Estimated
Start Date
Jul 2005
Primary Completion Date
Jan 2008Actual
Completion Date
Jun 2008Actual
Brief Summary
The purpose of this study is to investigate whether injections of botulinum toxin Type A into the bladder are safe and effective in treating overactive bladder.
Overactive Bladder
Urinary Incontinence
botulinum toxin Type A
Placebo
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Must be between 18-85 years old
Must have been diagnosed by his/her doctor with overactive bladder at least 6 months ago
Must weigh at least 50 kg (110 lbs)
Must be willing and able to record information regarding bladder function into a diary (provided)
Must be willing and able to complete the entire course of the study
Exclusion Criteria:
Cannot currently be catheterizing as a way to control incontinence
Must not have used botulinum toxin type A or any other botulinum toxin previously for any condition